|
1) Vanholder R, Smet RD, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63: 1934-43
|
|
|
|
2) Vanholder R, Glorieux G, Smet RD, et al. New insights in uremic toxins. Kidney Int. 2003; 84: S6-10
|
|
|
|
|
|
3) Vanholder R, Van Laecke S, Glorieux G. What is new in uremic toxicity？ Pediatr Neprol. 2008; 23: 1211-21
|
|
|
|
|
|
4) Cohen G, Glorieux G, Thomalley P, et al. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. Nephrol Dial Transplant. 2007; 22: 3381-90
|
|
|
|
|
|
5) Andress DL, Howard GA, Birnbaum RS: Identification of low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int. 1991; 39: 942-5
|
|
|
|
|
|
6) Disthabanchong S, Hassan H, McConkey CL, et al. Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. Kidney Int. 2004; 65: 897-903
|
|
|
|
|
|
7) Steddon SJ, Mcintyre CW, Schrieder NJ, et al. Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu. Nephrol Dial Transplant. 2004; 19: 3078-83
|
|
|
|
|
|
8) Wangner MS, Stracke S, Jehle PM, et al. Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts. Nephron. 2000; 84: 158-66
|
|
|
|
|
|
9) Massry SG. Is parathyroid hormone a uremic toxin？ Nephron. 1977; 19: 125-30
|
|
|
|
|
|
10) Ubara Y, Fushimi T, Tagami T, et al. Histomorphometric features of bone in patients with primary and secondary hypoparathyroidism. Kidney Int. 2003; 63: 1809-16
|
|
|
|
|
|
11) Yajima A, Inaba M, Tominaga Y, et al. Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int. 2008; Jun 4(Epub ahead of print)
|
|
|
|
|
|
12) Motojima M, Hosokawa A, Yamato H, et al. Uremic toxins proximal tubular injury via organic anion transpoter-1-mediated uptake. Br J Pharmacol. 2002; 135: 555-63
|
|
|
|
|
|
13) Deguchi T, Kusuhara H, Takedate A, et al. Characterization of uremic toxin transport by organic anion transporters in kidney. Kidney Int. 2004; 65: 162-74
|
|
|
|
|
|
14) Motojima M, Hosokawa A, Yamato H, et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-κB and free radical in proximal tubular cells. Kidney Int. 2003; 63: 1671-80
|
|
|
|
|
|
15) Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol. 2002; 13: 1711-20
|
|
|
|
|
|
16) Enomoto A, Niwa T. Role of organic anion transporters in the progression of chronic renal failure. Ther Apher Dial. 2007; 11(suppl. 1): S27-31
|
|
|
|
|
|
17) Iwasaki Y, Yamato H, Kono-Nii T, et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant. 2006; 21: 2768-74
|
|
|
|
|
|
18) Kono-Nii T, Iwasaki Y, Uchida M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int. 2007 Jan 31; [Epub ahead of print]
|
|
|
|
|
|
19) Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002; 39: 525-32
|
|
|
|
|
|
20) Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318: 1315-21
|
|
|
|
|
|
21) Schurman L, McCarthy AD, Seclinsky C, et al. Metformin reverets deleterious effects of advanced glycation end-products(AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes. 2008; 116: 333-40
|
|
|
|
|
|
22) Franke S, Siggelkow H, Wolf G, et al. Advanced glycation end products influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem. 2007; 113: 154-61
|
|
|
|
|
|
23) Shiraki M, Kuroda T, Tanaka, S, et al. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008; 26: 93-100
|
|
|
|
|
|
24) Panuccio V, Cutrupi S, Pizzini P, et al. Neuropeptide Y and markers of osteoblast activity in dialysis patients: A cross-sectional study. Am J Kidney Dis. 2007; 50: 1001-8
|
|
|
|
|
|
25) Jankowske J, van der Giet M, Jankowski V, et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS epression. J Clin Invest. 2003; 112: 256-64
|
|
|
|
|
|
26) Yano S, Yamaguchi T, Kanazawa I, et al. The uraemic toxin phenylacetic acid inhibits osteoblastic prolferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. Nephrol Dial Transplant. 2007; 22: 3160-5
|
|
|
|
|
|
27) Miyata T, Oda O, Inagi R, et al. β2-microgloblin modified with advanced glycation endproducts is a major component of hemodialysis -associated amyloidosis. J Clin Invest. 1993; 92: 1243-52
|
|
|
|
|
|
28) Cheung AK, Rocco MV, Yan G, et al. Serum β2-microgloblin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol. 2006; 17: 546-55
|
|
|
|
|
|
29) Menaa C, Esser E, Sprague SM. β2-microgloblin stimulates osteoclast formation. Kidney Int. 2008; 73: 1275-81
|
|
|
|
|
|
30) Grzegorzewska AE, Mlot-Michalska M. Bone pain in dialysis patients is not associated with bone mineral density but with serum concentration of small uremic toxis. Advances in Medical Sciences. 2007; 52: 228-31
|
|
|
|
|